335 related articles for article (PubMed ID: 34011560)
1. Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER
Servetto A; Kollipara R; Formisano L; Lin CC; Lee KM; Sudhan DR; Gonzalez-Ericsson PI; Chatterjee S; Guerrero-Zotano A; Mendiratta S; Akamatsu H; James N; Bianco R; Hanker AB; Kittler R; Arteaga CL
Clin Cancer Res; 2021 Aug; 27(15):4379-4396. PubMed ID: 34011560
[TBL] [Abstract][Full Text] [Related]
2. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
3. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
[TBL] [Abstract][Full Text] [Related]
4. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Mouron S; Manso L; Caleiras E; Rodriguez-Peralto JL; Rueda OM; Caldas C; Colomer R; Quintela-Fandino M; Bueno MJ
Breast Cancer Res; 2021 Feb; 23(1):21. PubMed ID: 33579347
[TBL] [Abstract][Full Text] [Related]
5. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER
Mao P; Cohen O; Kowalski KJ; Kusiel JG; Buendia-Buendia JE; Cuoco MS; Exman P; Wander SA; Waks AG; Nayar U; Chung J; Freeman S; Rozenblatt-Rosen O; Miller VA; Piccioni F; Root DE; Regev A; Winer EP; Lin NU; Wagle N
Clin Cancer Res; 2020 Nov; 26(22):5974-5989. PubMed ID: 32723837
[TBL] [Abstract][Full Text] [Related]
6. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
[TBL] [Abstract][Full Text] [Related]
7. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Balko JM; Mayer IA; Sanders ME; Miller TW; Kuba MG; Meszoely IM; Wagle N; Garraway LA; Arteaga CL
Mol Cancer Ther; 2012 Oct; 11(10):2301-5. PubMed ID: 22879364
[TBL] [Abstract][Full Text] [Related]
8. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
[TBL] [Abstract][Full Text] [Related]
9. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of ER
Giltnane JM; Hutchinson KE; Stricker TP; Formisano L; Young CD; Estrada MV; Nixon MJ; Du L; Sanchez V; Ericsson PG; Kuba MG; Sanders ME; Mu XJ; Van Allen EM; Wagle N; Mayer IA; Abramson V; Gόmez H; Rizzo M; Toy W; Chandarlapaty S; Mayer EL; Christiansen J; Murphy D; Fitzgerald K; Wang K; Ross JS; Miller VA; Stephens PJ; Yelensky R; Garraway L; Shyr Y; Meszoely I; Balko JM; Arteaga CL
Sci Transl Med; 2017 Aug; 9(402):. PubMed ID: 28794284
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
[TBL] [Abstract][Full Text] [Related]
12. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
[TBL] [Abstract][Full Text] [Related]
13. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
14. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
15. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
16. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Miller TW; Balko JM; Fox EM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; Jiang A; Smith RA; Maira SM; Manning HC; González-Angulo AM; Mills GB; Higham C; Chanthaphaychith S; Kuba MG; Miller WR; Shyr Y; Arteaga CL
Cancer Discov; 2011 Sep; 1(4):338-51. PubMed ID: 22049316
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
[TBL] [Abstract][Full Text] [Related]
19. Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.
McGrath MK; Abolhassani A; Guy L; Elshazly AM; Barrett JT; Mivechi NF; Gewirtz DA; Schoenlein PV
Front Endocrinol (Lausanne); 2024; 15():1298423. PubMed ID: 38567308
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
